tiprankstipranks
Trending News
More News >
Harrow Health (HROW)
:HROW
US Market
Advertisement

Harrow Health (HROW) AI Stock Analysis

Compare
396 Followers

Top Page

HROW

Harrow Health

(NASDAQ:HROW)

Rating:57Neutral
Price Target:
$33.00
▼(-0.63% Downside)
Harrow Health's strong revenue growth and positive earnings call outlook are overshadowed by significant financial risks, including high debt and cash flow concerns. Mixed technical indicators and poor valuation metrics further weigh down the stock's attractiveness.
Positive Factors
Acquisition and Commercial Rights
Harrow has acquired exclusive U.S. commercial rights to two ophthalmology biosimilars, strengthening its commercial portfolio of ophthalmic drugs.
Strategic Partnerships
Harrow announced a definitive agreement with Samsung Bioepis for the exclusive U.S. commercial rights to two ophthalmology biosimilars, including BYOOVIZ and OPUVIZ.
Negative Factors
Product Development Risks
Risks include lower-than-projected market uptake of products and the inability to develop and secure regulatory approval of pipeline products.
Regulatory and Market Risks
The U.S. launch date of OPUVIZ is yet to be determined due to ongoing litigation involving biosimilar manufacturers.

Harrow Health (HROW) vs. SPDR S&P 500 ETF (SPY)

Harrow Health Business Overview & Revenue Model

Company DescriptionHarrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
How the Company Makes MoneyHarrow Health generates its revenue through the sale of proprietary ophthalmic pharmaceutical products and compounded medications to healthcare providers and institutions. The company's revenue streams include direct sales of its branded products, licensing agreements, and royalties from its intellectual property portfolio. Harrow Health also benefits from strategic partnerships with other pharmaceutical companies, allowing it to expand its market reach and enhance its product offerings. The company's focus on niche markets and specialty formulations helps in maintaining competitive pricing and customer loyalty, contributing significantly to its earnings.

Harrow Health Earnings Call Summary

Earnings Call Date:May 08, 2025
(Q1-2025)
|
% Change Since: 40.78%|
Next Earnings Date:Aug 11, 2025
Earnings Call Sentiment Positive
Harrow demonstrated strong revenue growth and cash flow, along with successful strategic initiatives in product launches and market access. However, the quarter was marred by seasonal revenue weakness and significant one-time expenses. The company's outlook remains positive with expectations for growth in the remainder of the year.
Q1-2025 Updates
Positive Updates
Significant Revenue Growth
Harrow reported a 38% year-over-year revenue growth in the first quarter of 2025.
Record Cash Flow
The company delivered a record $19.7 million in cash flow from operations.
VEVYE Revenue Increase
VEVYE revenue rose 35% sequentially, from $16 million in Q4 2024 to $21.5 million in Q1 2025.
Successful Launch of VEVYE Access for All Program
Post-launch, both new prescriptions and weekly VEVYE prescribers at PhilRx quadrupled.
Infrastructure Expansion
The VEVYE team has grown to over 80 sales and marketing professionals, with additional expansion in other teams.
Positive Market Response for TRIESENCE
Market access initiatives for TRIESENCE are expected to unlock about 40% of the overall market, showing significant sales momentum.
Strong ImprimisRx Performance
April appears to be a record month for ImprimisRx, indicating consistent performance.
Negative Updates
Seasonal Revenue Weakness
First quarter revenues for some segments were softer than expected due to seasonality.
One-time Expenses Impact
The first quarter faced challenges from one-time expenses totaling $3.7 million.
IHEEZO Sales Impact
IHEEZO's first quarter sales were impacted by elevated stocking activity at the end of 2024.
Specialty Branded Products Volatility
Volatility in gross to net estimates for specialty branded products caused a reduction in recognizable revenue for the period.
Company Guidance
During Harrow's First Quarter 2025 Earnings Conference Call, the company provided guidance indicating a strong outlook for the remainder of the year. They aim to achieve their 2025 revenue target of over $280 million, requiring approximately $232 million in revenue across the next three quarters. In Q1 2025, Harrow's revenue grew by 38% year-over-year, with standout performance from VEVYE, which saw a 35% sequential revenue increase to $21.5 million. Harrow anticipates VEVYE will generate at least $100 million in revenue by year-end. IHEEZO is expected to deliver over $50 million, and the specialty branded products, including TRIESENCE, are projected to contribute at least $50 million. The ImprimisRx compounding business is on track to deliver more than $80 million. Harrow also reported a record $19.7 million in cash flow from operations in Q1 and discussed strategic initiatives such as the VEVYE Access for All program, which has quadrupled new prescriptions and prescribers within seven weeks of launch.

Harrow Health Financial Statement Overview

Summary
Harrow Health demonstrates strong revenue growth but faces significant challenges with profitability and high leverage. The negative net profit margin and high debt-to-equity ratio indicate financial risk, despite some operational efficiency improvements.
Income Statement
65
Positive
Harrow Health has shown strong revenue growth, increasing from $48.87M in 2020 to $212.86M in TTM (Trailing-Twelve-Months) 2025, indicating a solid growth trajectory. The gross profit margin remains healthy at 74.5% TTM, despite a negative net profit margin of -10.2% TTM, reflecting ongoing profitability challenges. EBIT margin stands at 2.1% TTM, with EBITDA margin at 8.8% TTM, suggesting some improvement in operational efficiency but still below industry norms.
Balance Sheet
55
Neutral
The company's balance sheet shows a concerning debt-to-equity ratio of 4.07 TTM, indicating high leverage, which presents financial risk. Return on equity is negative at -38.4% TTM, due to persistent net losses. The equity ratio is low at 15.5% TTM, signaling a reliance on debt financing, which could be risky if earnings do not improve.
Cash Flow
50
Neutral
Harrow Health's cash flow performance is mixed, with free cash flow remaining negative at -$36.61M TTM, indicating cash generation challenges. The operating cash flow to net income ratio is positive at 0.10 TTM, reflecting some cash generation from operations, but the free cash flow to net income ratio is negative, highlighting ongoing cash burn issues.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue199.61M130.19M88.59M72.48M48.87M
Gross Profit150.37M90.55M63.21M54.26M34.41M
EBITDA20.00M9.95M-3.10M4.26M3.49M
Net Income-17.48M-24.41M-14.09M-18.01M-3.36M
Balance Sheet
Total Assets388.97M312.16M157.02M98.33M57.47M
Cash, Cash Equivalents and Short-Term Investments47.25M82.77M96.27M50.67M32.56M
Total Debt228.83M190.50M104.17M77.96M23.53M
Total Liabilities319.67M241.75M130.14M87.40M30.65M
Stockholders Equity69.65T70.77M27.24M11.29M27.18M
Cash Flow
Free Cash Flow-60.88M-148.71M-6.07M-23.43M-2.09M
Operating Cash Flow-22.20M3.84M1.71M5.08M-1.10M
Investing Cash Flow-33.16T-152.55M-1.74M-18.69M-981.00K
Financing Cash Flow28.53M126.53M54.14M51.47M1.43M

Harrow Health Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price33.21
Price Trends
50DMA
32.11
Positive
100DMA
28.79
Positive
200DMA
32.73
Positive
Market Momentum
MACD
0.21
Positive
RSI
49.49
Neutral
STOCH
43.53
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HROW, the sentiment is Neutral. The current price of 33.21 is below the 20-day moving average (MA) of 34.66, above the 50-day MA of 32.11, and above the 200-day MA of 32.73, indicating a neutral trend. The MACD of 0.21 indicates Positive momentum. The RSI at 49.49 is Neutral, neither overbought nor oversold. The STOCH value of 43.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HROW.

Harrow Health Risk Analysis

Harrow Health disclosed 58 risk factors in its most recent earnings report. Harrow Health reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Harrow Health Peers Comparison

Overall Rating
UnderperformOutperform
Sector (47)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
82
Outperform
$519.86M7.4543.61%10.13%3.86%-2.60%
75
Outperform
$956.23M31.8016.16%22.61%-63.00%
70
Outperform
$1.50B-5.19%30.26%-173.36%
68
Neutral
$981.44M7.8519.90%8.05%-8.46%
59
Neutral
$1.01B-15.57%3.08%-247.82%
57
Neutral
$1.21B-37.23%53.49%33.18%
47
Neutral
C$187.86M-2.63-23.77%3.19%17.01%2.49%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HROW
Harrow Health
33.21
-2.73
-7.60%
PCRX
Pacira Pharmaceuticals
23.77
12.07
103.16%
SIGA
SIGA Technologies
8.55
0.68
8.64%
ANIP
ANI Pharmaceuticals
69.01
11.11
19.19%
AMPH
Amphastar Pharmaceuticals
21.62
-21.23
-49.54%
COLL
Collegium Pharmaceutical
32.94
-2.56
-7.21%

Harrow Health Corporate Events

Executive/Board ChangesShareholder Meetings
Harrow Health Approves Key Proposals at Annual Meeting
Neutral
Jun 20, 2025

On June 18, 2025, Harrow Health held its Annual Meeting of Stockholders, where all matters submitted for a vote were approved. The meeting included the election of four directors, approval of the 2025 Incentive Stock and Awards Plan, ratification of Crowe LLP as auditors, and advisory votes on executive compensation and its frequency.

The most recent analyst rating on (HROW) stock is a Buy with a $57.00 price target. To see the full list of analyst forecasts on Harrow Health stock, see the HROW Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 01, 2025